Highlights

  • Xenon Pharmaceuticals (NASDAQ:XENE) shares fell 3.4%, trading volume dropped 85% below daily average.
  • Goldman Sachs reduced its target price on XENE stock from USD60.00 to USD52.00.
  • Consensus rating on Xenon remains “Moderate Buy” with average target price of USD54.82.

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) declined by 3.4% during mid-day trading on Monday, reaching an intraday low of USD31.57 before slightly recovering to close at USD31.64. The trading volume stood at 82,081 shares, sharply lower than the company’s average daily volume of 558,820 shares, reflecting an 85% drop.

In a recent research update, Goldman Sachs Group cut its price objective on Xenon shares from USD60.00 to USD52.00, while maintaining a “Buy” rating. The adjustment suggests tempered expectations amid broader market and sector-specific pressures, though the bank retains a favorable view on the stock’s potential relative to peers.

Additional analyst activity has reflected a range of views. Evercore ISI initiated coverage on May 14th with an “Outperform” rating and a USD55.00 price target. Similarly, HC Wainwright reaffirmed a “Buy” rating and a USD53.00 target. However, Wall Street Zen downgraded the stock from “Hold” to “Sell” in a note dated May 21st, citing possible risks or valuation concerns. Meanwhile, Wells Fargo & Company revised its target from USD50.00 to USD47.00, assigning an “Overweight” rating.

Xenon’s current market capitalization is approximately USD2.45 billion. The stock trades at a P/E ratio of -11.28, indicating negative earnings, and has a beta of 1.09, suggesting modest volatility relative to the broader market. The company’s 50-day moving average is USD32.94, while its 200-day moving average is USD36.31, reflecting recent declines.

For Q1 earnings, Xenon reported a loss of USD0.83 per share, beating consensus estimates of a USD0.90 loss. Quarterly revenue reached USD7.5 million, outperforming expectations of USD1.64 million. Analysts forecast a full-year loss of approximately USD3.10 per share for fiscal 2025.

On the investment side, institutional ownership remains high, with 95.45% of the stock held by institutional investors. Recent entries by firms such as Vident Advisory LLC, Magnetar Financial LLC, and Caitong International Asset Management indicate continued interest despite recent volatility.

Xenon Pharmaceuticals focuses on treatments for neurological disorders and is currently advancing its lead candidate XEN1101, which is in Phase 3 clinical trials for epilepsy and related conditions.